Bacterial biofilms are involved in a multitude of serious chronic infections. In recent years, modeling of biofilm infection in vitro has led to the identification of microbial determinants that govern biofilm development. However, we lack information as to whether the biofilm formation mechanisms identified in vitro have relevance for biofilm-associated infection. Here, we discuss the molecular basis of biofilm formation. Staphylococci and Pseudomonas aeruginosa are used to illustrate key points because their biofilm development process has been well studied. We focus on in vivo findings, such as obtained in animal infection models, and critically evaluate the in vivo relevance of in vitro findings. Although conflicting results about the role of quorum sensing in biofilm formation have been obtained, we argue that integration of in vitro and in vivo studies allows a differentiated view of this mechanism as it relates to biofilm infection.
Recognizing that laboratory conditions poorly represent microbial life in nature, William J. Costerton coined the term ''biofilm'' in 1978 to describe surface-attached microbial agglomerations (Costerton et al., 1978) . Since that early realization, biofilm research has grown into a recognized field of study within microbiology. Notably, biofilms play an immensely important role in human health, as they shelter bacteria from antibiotics and host defense during infection (Costerton et al., 1999) . The percentage of bacterial infections that involve biofilms varies depending on the reporting agency, with estimates of 65% of all infections according to the Centers for Disease Control and 80% according to the National Institutes of Health. Sources of infection include commensal microbes that live on human body surfaces, such as staphylococci, and originally environmental microbes, such as Pseudomonas aeruginosa.
In the last three decades, investigators have developed multiple ways to investigate biofilms using in vitro models (McBain, 2009) . Ranging from simple attachment tests in microtiter plates to sophisticated biofilm reactors, and from qualitative microscopic examination to elaborated mathematical evaluation of images acquired by confocal laser-scanning microscopy (CLSM), these in vitro models have provided detailed insights into the processes that lead to the formation of biofilms. In particular, the combination of these approaches with molecular biology techniques has produced important information related to the genetic requirements of biofilm development. Procedures such as transposon mutagenesis and genome-wide screening led to the identification of genes involved in the production of biofilm matrix components and the regulatory principles that govern biofilm development (Friedman and Kolter, 2004a; Heilmann et al., 1996; Simm et al., 2004) . Cloning of biofilm determinants and the production of isogenic deletion mutants subsequently enabled investigators to further decipher the precise roles of these genes in biofilm formation.
However, biofilms are very complex communities that interact with the human body in a multitude of ways that are hard to mimic using in vitro setups. Unfortunately, although in vitro biofilm studies have greatly advanced our understanding of biofilm development, in vivo investigation of the molecular processes that occur during biofilm-associated human disease has trailed behind.
Among the bacteria that are involved in biofilm-associated infections, the Gram-negative bacterium P. aeruginosa has received the most attention. This organism is particularly notorious for causing severe chronic infection in patients with cystic fibrosis (CF) . However, adequate animal models of biofilm-associated infection in CF have not been available until recently. Although the physiology and especially the gene regulatory processes of P. aeruginosa have been well studied, the in vivo relevance of these processes for the most part remains to be established.
The Gram-positive bacteria Staphylococcus aureus and S. epidermidis are the most frequent causes of nosocomial infections on indwelling medical devices (Otto, 2008) . Because device-related infections occur extremely frequently and are commonly associated with biofilms, these bacteria can be regarded as the most important etiological agents of biofilmassociated infections. Staphylococci are difficult to manipulate on a genetic level, although considerable advances have recently been made in this field. On the other hand, it is easier to model device-related infections than CF in animals.
Biofilm research is also being performed in many other microorganisms, such as Escherichia and Vibrio ssp. (Beloin et al., 2008; Yildiz and Visick, 2009 ). However, given the wealth of information available in particular for P. aeruginosa and staphylococci, we chose to focus on these organisms in this work. First, we outline the mechanisms of biofilm development, focusing on general principles rather than species-specific peculiarities. We then provide a critical assessment of whether in vitro findings bear on the in vivo situation, or whether the in vivo significance of biofilm mechanisms was established using animal infection models. Finally, we evaluate possible avenues for the development of antibiofilm drugs.
Biofilm Infections
As they proceed, most bacterial infections involve biofilms, but there are some examples of biofilm-associated infections in which the contribution of biofilms is particularly characteristic and important. These include infections on indwelling medical devices such as intravascular catheters, prosthetic vascular grafts, cardiac devices, prosthetic joints, and shunts. Coagulase-negative staphylococci, mainly S. epidermidis, are the most frequent causes of these types of infections (Rogers et al., 2009) . In addition to the strong biofilm-forming capacity of many S. epidermidis strains, the sheer abundance of S. epidermidis on human skin may explain its frequent involvement in device-related biofilm infection (Otto, 2009) .
Biofilm infections may also develop independently of indwelling medical devices, e.g., in native valve endocarditis, open wounds, or dental plaque. Although they are not as frequent as many other biofilm-associated infections, biofilms in patients with chronic CF have received much attention owing to the high morbidity associated with the disease. For a long time, CF has been in the center of medical-biofilm research, and therefore much of what we know about biofilms was first investigated in the main CF pathogen, P. aeruginosa. Of note, the lungs of CF patients are not infected solely by P. aeruginosa; however, in chronic CF infections, this bacterium tends to outcompete other bacteria that infect CF patients in earlier stages of the disease, such as Burkholderia cepacia and S. aureus (Rajan and Saiman, 2002) . This phenomenon appears to be specific for CF infections, as P. aeruginosa does not outcompete other biofilm bacteria in other infections, such as chronic wounds (Kirketerp-Møller et al., 2008) .
In Vivo Biofilm Models
Investigators have modeled indwelling device-related infection using a series of different approaches and animals. The easiest and most frequently used model includes the placement of a piece of catheter or other plastic tubing under the skin of a mouse at the dorsum (Kadurugamuwa et al., 2003; Rupp et al., 1999a) . Often, biofilms are established on the tubing before insertion, which has the advantage of enabling reproducibility, in contrast to the alternative method of injecting bacteria into the lumen of already inserted tubing. This model is supposed to mimic biofilms that originate from contaminated catheters quite closely; however, like many other animal models, it suffers from the fact that the inocula used greatly exceed the number of bacteria from which such an infection is supposed to start in a real-life scenario. In models of device-related endocarditis, the inocula are smaller and biofilm infection may actually progress, but these models are surgically more challenging and require larger animals such as rats or rabbits (Hirano and Bayer, 1991; Xiong et al., 2005) . Tissue cage models, which were first established in guinea pigs but are also often performed in mice, use little, hollow, ball-like cages in which catheter tubing is placed and assayed for biofilm development (Zimmerli et al., 1982) .
Biofilm-associated wound infection is difficult to mimic, because the skin of commonly used test animal species is inherently different from human skin. Pig-skin infection appears to come as close as possible to human-skin infection (Roche et al., 2012) , but pigs are not available as test animals for most researchers. Similarly, dental plaque formation is extremely difficult to simulate.
Because P. aeruginosa has been the key subject of biofilm studies, biofilm researchers have tried for a long time to establish an animal model of CF biofilm-associated lung infection. Earlier models have been criticized as not being representative of chronic infection, for two main reasons (Hoffmann, 2007) : first, the most commonly used P. aeruginosa strain, PAO1, is a nonmucoid isolate that causes acute types of infection that are not representative of the clinical situation in chronic infection; second, the bacteria were embedded in an artificial biofilm (e.g., made of agar) to prevent mechanical clearing. However, a model that uses a clinical isolate without the need for artificial embedding was recently established (Hoffmann et al., 2005) .
Establishing a Biofilm Infection: Attachment
Biofilm formation is commonly considered to occur in three main stages: (1) attachment to a surface; (2) proliferation and formation of the characteristic, mature biofilm structure; and (3) detachment, which is also often called dispersal (O'Toole et al., 2000) . Recent research has provided molecular insight into all three stages (Figure 1 ).
Many studies have investigated the attachment of biofilmforming bacteria to abiotic surfaces. In general, the bacterial characteristics that determine the degree of attachment to such surfaces have a physicochemical nature. Most notable of these is hydrophobicity, which is determined by the overall composition of the bacterial surface. Some specific determinants of attachment have been reported; however, it needs to be stressed that the techniques used to investigate attachment determinants are often simple and similar to those employed for the investigation of biofilm formation overall. Consequently, there is a significant overlap between factors that have been reported to be involved in the attachment and proliferative stages of biofilm development. For example, in S. aureus and S. epidermidis, teichoic acids and the surface protein autolysin were linked to abiotic surface attachment (Gross et al., 2001; Heilmann et al., 1997) , but it can be assumed that their impact is indirect, via alteration of surface hydrophobicity. The S. epidermidis autolysin AtlE was shown to have a role in device-related infection (Rupp et al., 2001) , but it is difficult to judge whether the detected effect was due to attachment or the primary role of AtlE in cell growth and division. In P. aeruginosa, flagella (O'Toole and Kolter, 1998), pili (Dé ziel et al., 2001) , fimbria (Vallet et al., 2001) , extracellular DNA (eDNA) (Whitchurch et al., 2002) , and the Psl exopolysaccharide (Ma et al., 2009) were attributed functions in surface attachment. Several of these factors work by facilitating the transport of P. aeruginosa to surfaces where it can form a biofilm, reflecting the fact that P. aeruginosa is motile (in contrast to staphylococci). However, it is certainly debatable whether the requirement for motility to reach a surface represents an attachment phenomenon in the strictest sense. Psl and eDNA also were reported to affect biofilm formation in later stages; a specific role for these factors in attachment is thus questionable for the reasons outlined above.
Biofilm attachment to abiotic surfaces may play an important role when biofilms persist in the hospital setting (e.g., on medical instruments and doorknobs) as fomites of infection. However, attachment to an abiotic surface is very likely only of minor importance for biofilm formation in vivo. Attachment to tissue or medical devices in the human body is mainly governed by the interaction of bacteria with human matrix proteins, which effectively cover devices soon after insertion. In staphylococci, the major underlying molecules are a class of surface-attached bacterial proteins termed microbial surface components recognizing adhesive matrix molecules (MSCRAMMs; Clarke and Foster, 2006; Foster and Hö ö k, 1998 ). Many MSCRAMMS have been shown to have a role in staphylococcal infection or colonization in vivo. These include fibronectin-binding (McElroy et al., 2002) and fibrinogen-binding (Josefsson et al., 2001) proteins, and the S. aureus surface protein SasX, which was linked to an ongoing outbreak of methicillin-resistant S. aureus (Li et al., 2012) . Furthermore, MSCRAMMs were shown in multiple in vitro assays to promote adhesion to human matrix proteins such as fibrinogen (Pei et al., 1999) , fibronectin (Maxe et al., 1986) , and others. In the case of P. aeruginosa, indications for a role in attachment of specific determinants during infection have been exclusively derived from in vitro experiments, often using only abiotic surfaces. Therefore, confirmation that specific P. aeruginosa attachment factors play a role during infection has to await detailed in vivo investigation.
Formation of a Biofilm: Matrix Formation
After attachment to tissue or matrix-covered devices is accomplished, infectious bacterial biofilms grow by proliferation and production of an extracellular matrix. The function of the matrix is to provide adhesion between bacterial cells, thereby enabling the formation of a multilayered biofilm. In vitro evidence indicates that the biofilm matrix consists of a multitude of components of different chemical natures, including exopolysaccharides, proteins, eDNA, and other polymers. These components may also facilitate the formation of bacterial agglomerations that do not necessarily constitute a biofilm, and provide protection from antibiotics and host defenses independently of biofilm formation (Mai et al., 1993; Vuong et al., 2004c) .
S. aureus and S. epidermidis produce an exopolysaccharide named polysaccharide intercellular adhesin (PIA, also called poly-N-acetyl glucosamine [PNAG]; Cramton et al., 1999; Mack et al., 1996; Maira-Litrá n et al., 2002; Figure 2) . PIA/ PNAG is probably the most important component of the extracellular matrix in staphylococci, although there is evidence that in vitro and in vivo staphylococcal biofilms can form without PIA/PNAG . In such cases, other matrix components substitute for the missing exopolysaccharide. An important feature of the PIA/PNAG molecule is its partial deacetylation, which produces positively charged residues that likely have an important role in interacting with other, negatively charged matrix components, resulting in a tightly connected matrix network (Vuong et al., 2004a) . The importance of PIA/ PNAG in biofilm-associated infection was demonstrated in several animal infection models (Begun et al., 2007; Kropec et al., 2005; Rupp et al., 1999a Rupp et al., , 1999b Vuong et al., 2004a) . Importantly, PIA/PNAG is also found in other biofilm-forming bacteria, including many staphylococci and even Gram-negative bacteria (Kaplan et al., 2004; Wang et al., 2004) .
Teichoic acids are characteristic major components of the cell surface in Gram-positive bacteria (Glaser, 1973) . Teichoic acids are negatively charged and have been shown to contribute to biofilm formation in staphylococci. Most likely, they interact with other surface polymers and function as a scaffold for protein attachment (Gross et al., 2001; Sadovskaya et al., 2005) .
P. aeruginosa produces three exopolysaccharides: the glucose-rich Pel polysaccharide (Friedman and Kolter, 2004b) , the mannose-rich Psl polysaccharide (Friedman and Kolter, 2004b) , and alginate (Evans and Linker, 1973; Govan and Deretic, 1996; Høiby, 1974) . Alginate is an acylated polysaccharide composed of guluronic acid (GulUA) and mannuronic acid (ManUA) monomers (Figure 2) . A wealth of studies have provided 
Phases of In Vivo Biofilm Development
Biofilms develop via initial attachment, which depends on transport of the bacteria to a surface that is passive in the case of nonmotile bacteria such as staphylococci (yellow), and active in the case of motile bacteria such as P. aeruginosa (red). Attachment itself is governed by specific protein-protein interactions of the bacterial surface with human matrix proteins. Attachment to an abiotic surface such as a catheter depends on bacterial surface hydrophobicity, but this mechanism is believed to have minor importance in vivo. Subsequent steps do not differ in principle between motile and nonmotile bacteria. They involve proliferation, embedding in an extracellular matrix, and maturation. The latter depends on cell-cell disruptive factors, recently identified to be primarily surfactants. Strong production of surfactants, which are controlled by QS, leads to biofilm detachment (dispersal). In the case of motile bacteria, upregulation of motility, starting in the center of the biofilm mushroom caps, assists dispersal.
detailed information about the genetic regulation of the production of these polysaccharides. For example, production was reported to be regulated in a way opposite to that observed for factors involved in acute infection (Goodman et al., 2009 ). Importantly, alginate is overproduced during the establishment of a chronic CF infection, resulting in what is called a mucoid phenotype (Evans and Linker, 1973) . The role of these biofilm polysaccharides in CF has not yet been addressed using defined genetic mutants and animal infection models, despite early discovery of the genes involved in alginate biosynthesis (Deretic et al., 1987; Goldberg and Ohman, 1984) . However, it was shown that alginate biosynthesis contributes to virulence in acute forms of P. aeruginosa infection (Goldberg et al., 1995) .
Proteins may have an accessory or a primary (e.g., in the absence of staphylococcal PIA) role in formation of the biofilm matrix . In S. epidermidis, a protein called accumulation-associated protein (Aap) contributes to the establishment of intercellular connections by forming fibrils on the cell surface (Banner et al., 2007; Hussain et al., 1997; Rohde et al., 2005) . In S. aureus and S. epidermidis, additional surface proteins such as protein A, the S. aureus surface proteins SasC and SasG, extracellular matrix binding protein (Embp), biofilm-associated protein (Bap), and the fibronectin-binding proteins FnbpA and FnbpB were implicated in matrix formation (Christner et al., 2010; Corrigan et al., 2007; Cucarella et al., 2001; Merino et al., 2009; O'Neill et al., 2008; Schroeder et al., 2009) . Recent data indicate that in vitro biofilm formation of S. aureus as a species, in particular among methicillin-resistant strains, may rely more on eDNA and proteins, whereas PIA/ PNAG may play a more important role in S. epidermidis and methicillin-susceptible S. aureus (Izano et al., 2008; O'Neill et al., 2007; Pozzi et al., 2012 ). An in vivo role of several staphylococcal proteinaceous biofilm factors was established in animal infection models (Cucarella et al., 2001; Shinji et al., 2011) . However, in many cases it is unclear whether the observed effects are due to a contribution to biofilm development, tissue attachment, or biofilm-independent immune evasion mechanisms. Recent findings in P. aeruginosa indicate that a protein called CdrA is involved in exopolysaccharide cross-linking (Borlee et al., 2010) ; however, as yet, there is no in vivo evidence for a role of proteinaceous matrix components in P. aeruginosa CF infection.
In recent years, it was found that eDNA, which is released from dying cells, is a component of the extracellular biofilm matrix (Whitchurch et al., 2002) . DNA is a polyanionic molecule that is believed to interact with other matrix polymers of opposite charge, thereby contributing to the matrix network in a way similar to that observed for other polymers with distinct charge properties. In many biofilm-forming organisms, eDNA has an analogous effect (Rice et al., 2007; Thomas et al., 2008; Whitchurch et al., 2002) . Whether eDNA has a role in biofilm-associated infection is difficult to assess. Arguing against an in vivo role of bacterial eDNA is the presence of the potent DNase I in human serum, which (at least in vitro) has been shown to degrade bacterial biofilms that contain eDNA as a key matrix constituent (Kaplan et al., 2012; Whitchurch et al., 2002) .
Formation of a Structured Biofilm and Dispersal Mechanism: Quorum Sensing and Surfactants
When grown in vitro, mature biofilms have a characteristic mushroom-like structure that contains channels that are believed to be essential for providing nutrients to cells in deeper biofilm layers (O'Toole et al., 2000) . This indicates that in addition to the well-studied adhesive matrix components that mediate aggregation, biofilm maturation requires cell-cell disruptive factors. In the outmost layers of a biofilm or upon strong expression, such disruptive factors also cause cell detachment or dispersal.
Quorum sensing (QS), a phenomenon in which increased cell density triggers changes in gene expression, has received much attention as a regulator of biofilm formation and maturation. In staphylococci, QS is established by the accessory 
. Biofilm Exopolysaccharides in P. aeruginosa and Staphylococci
The major biofilm exopolysaccharide of staphylococci (and some other bacteria) is PIA (or PNAG), a homopolymer of beta-1,6-linked GlcNAc residues, and approximately one fourth of these residues become deacetylated after export. Deacetylation creates free amino groups that at neutral or acid pH give the molecule a cationic character (shown in blue). Major exopolysaccharides of P. aeruginosa are the ManUA/GulUA-based, negatively charged alginate (negative charges, red) and the mannose-rich neutral Psl. Manp, mannopyranose; Rhap; rhamnopyranose; Glcp, glucopyranose. gene regulator (Agr) system, which produces a secreted, posttranslationally modified peptide that interacts with a two-component system in an autofeedback loop, ultimately resulting in a considerable shift in gene expression patterns during the early stationary growth phase (Ji et al., 1995; Recsei et al., 1986 ; Figure 3 ). In general, Agr upregulates toxins and other acute virulence factors, and downregulates surface proteins such as MSCRAMMs. QS in P. aeruginosa is more complicated and comprises three systems that are interconnected in hierarchical order and together govern the expression of hundreds of genes (Schuster et al., 2003; Figure 4) . The Las system senses 3-oxo-C12-homoserine lactone, the Rhl system senses C4-homoserine lactone, and the Pqs system senses a specific quinolone referred to as Pseudomonas quinolone signal (PQS; Juhas et al., 2005) .
Recent reports have provided important insights into the QScontrolled factors that structure biofilms and cause detachment. In both P. aeruginosa and staphylococci, these are surfactants that are believed to function via the disruption of noncovalent interactions between biofilm cells and matrix molecules. The surfactant molecules responsible for biofilm maturation in staphylococci are phenol-soluble modulins (PSMs), which are amphipathic, a-helical peptides that are controlled by the Agr QS system in an exceptionally direct manner (Periasamy et al., 2012; Queck et al., 2008; Wang et al., 2011) . In P. aeruginosa, the QS-controlled surfactants are amphipathic glycolipids called rhamnolipids (Boles et al., 2005; Davey et al., 2003) . Rhamnolipid synthesis is induced in the center of the mushroom cap, which is consistent with it being subject to cell-density control (Lequette and Greenberg, 2005) . Because P. aeruginosa is a motile bacterium, dispersal may commence with the upregulation of motility, and recent evidence suggests that indeed both rhamnolipid and 
QS in Staphylococci
QS in staphylococci is exerted by the agr locus, which contains the agrA, agrC, agrD, and agrB genes (RNAII transcript) and RNAIII, the intracellular effector of the system, which also contains the hld gene for the PSM d-toxin. AgrD is a prepheromone that is exported and modified by AgrB, resulting in a characteristic thiolactone-containing autoinducing peptide (AIP). Activation of the AgrC/ AgrA two-component system by AIP binding leads to transcription of RNAIII and RNAII, with the latter leading to autofeedback and fast upregulation of agr and agr target expression at a certain threshold of cell density. Agr-regulated, biofilmrelevant genes are first and foremost PSMs, which are regulated by direct binding of AgrA to their promoters, rather than via RNAIII. In contrast, many MSCRAMMs are negatively regulated by RNAIII, indicating that tissue attachment is a mechanism that is no longer needed during later stages of infection.
type IV pili are involved in P. aeruginosa biofilm dispersal (Pamp and TolkerNielsen, 2007) . Notably, although the general principle of biofilm maturation and dispersal thus appears to be conserved among phylogenetically distinct bacteria, the surfactants differ in their chemical nature, indicating convergent evolution. Interestingly, both PSMs and rhamnolipid have additional functions in the killing of neutrophils, a key mechanism of immune evasion, especially in the case of S. aureus (Jensen et al., 2007; Wang et al., 2007) .
During infection, detachment is of the utmost importance because it may lead to the dissemination of a biofilm-associated infection. The role of Agr and PSM surfactants in dissemination was recently demonstrated in animal models of S. aureus and S. epidermidis catheter-related infection, underscoring the importance of surfactant-mediated QS control of biofilm-associated infection (Periasamy et al., 2012; Wang et al., 2011) .
Especially in staphylococci, biofilm maturation was also proposed to occur by enzymatic degradation of biofilm matrix components, most notably by proteases and nucleases (Boles and Horswill, 2008; Kiedrowski et al., 2011) . However, only some of these enzymes are under QS control. Importantly, QS does not regulate production of PIA/PNAG (Vuong et al., 2003) , and PIA/PNAG-degrading enzymes that were found in other bacteria (Kaplan et al., 2004) are apparently absent from staphylococci. Furthermore, there is no evidence for in vivo relevance of enzyme-based detachment. In fact, it was recently reported that nuclease does not contribute to in vivo biofilm dispersal in S. aureus (Beenken et al., 2012) .
In P. aeruginosa, QS appears to regulate Pel exopolysaccharide synthesis, although there are conflicting reports as to how production is affected (Sakuragi and Kolter, 2007; Ueda and Wood, 2009 ). Finally, it should be mentioned that D-amino acids were shown to trigger biofilm dispersal in the nonpathogenic Bacillus subtilis (Kolodkin-Gal et al., 2010) and, more recently, in S. aureus (Hochbaum et al., 2011) . However, the underlying regulated determinants are not known.
Biofilm Formation as a Lifestyle Change
The first report about the role of QS in bacterial biofilm formation described the P. aeruginosa Las system as being important for the formation of structured, extended biofilms, as a lasI mutant formed an undifferentiated, flat biofilm compared with the wildtype strain (Davies et al., 1998) . Subsequent research in staphylococci underscored the function of QS in biofilm structuring, but also showed that agr mutants formed a thicker rather than flatter biofilm compared with the wild-type strains (Vuong et al., 2000 (Vuong et al., , 2003 . Also in P. aeruginosa, further investigation of the relationship between QS and biofilm development produced results that could not be aligned with the initial, simple model of direct, positive control of biofilm formation by QS (Kirisits and Parsek, 2006) .
Similarly, the role of QS in biofilm-associated infection has remained a complicated issue. In P. aeruginosa, evidence for a significant role of QS in biofilm-associated CF infection is based on the detection of QS signals in the sputum of CF patients (Singh et al., 2000) . In S. epidermidis, a contrasting role for QS in catheter attachment and infiltration of surrounding tissue was shown (Vuong et al., 2004b) . Furthermore, although QS was reported to have a positive role in many infections, clinical isolates in both staphylococci and P. aeruginosa that were obtained from chronic biofilm-associated infections were often demonstrated to be QS mutants, directly arguing against a positive role for QS in biofilm development Traber et al., 2008; Vuong et al., 2004b) .
A model that unifies these conflicting results and offers a possible way to rationalize them is based on distinguishing two types of virulence, acute and chronic, and recognizing that QS is important for the expression of acute virulence and the formation of a differentiated biofilm with the capacity for dissemination, whereas chronic biofilm-associated infection develops with a downregulation and/or mutation of the QS system(s) (Figure 5 ). Reflecting the contrasting bacterial approaches to infection in cases of high or low QS activity, QS has been P. aeruginosa uses at least three QS systems, which are arranged in hierarchical order. The rhl system is under control of the las system, and both systems use an AHL signal that is produced by the LasI or RhlI AHL synthetases, respectively. Target genes are under control of the DNA-binding regulators LasR, RhlR, and QscR, defining the respective QS regulons. AHL synthetase genes are controlled by the corresponding regulator proteins, resulting in QS-characteristic autofeedback loops. The qsc system responds to but does not produce AHLs. In addition to controlling production of the qsc system's target genes, the QscR DNA-binding protein inhibits expression of the AHL-producing LasI and RhlI enzymes.
described as a lifestyle determinant of biofilm-forming pathogenic bacteria. Accordingly, the determinants of acute and chronic virulence are regulated by QS in an opposite fashion. In staphylococci, toxins and degradative exoenzymes as characteristic mediators of acute virulence are upregulated by QS, whereas nonaggressive colonization and biofilm factors such as MSCRAMMS are downregulated. Similarly, in P. aeruginosa, QS upregulates proteases while it downregulates the biofilm exopolysaccharide alginate. Recent findings provide further support for this model. In S. aureus, QS mutants are found in elevated numbers in chronic infection, but these mutants have lost the ability to infect other individuals, for which active QS is crucial (Shopsin et al., 2010) . In P. aeruginosa, it has been shown that QS mutants occur in increasing numbers in late stages of CF infection, whereas rhamnolipid production is maintained in earlier stages . Finally, cyclic diguanylate (c-di-GMP), a recently identified regulatory molecule that governs biofilm formation among many other mechanisms, was reported to have a key role in regulating ''lifestyle'' changes in many biofilm-forming bacteria (Gomelsky and Hoff, 2011; Hickman et al., 2005) . To date, however, there is no in vivo evidence for a role of c-di-GMP during biofilm infection. Despite recent insights, an important question remains unanswered: Does the entire population in chronic biofilms consist of QS mutants, or are some nonmutant cells reserved to potentially regain the ability to disseminate under changing environmental conditions? Commonly, clinical microbiology laboratories only culture one representative isolate from an infection; however, to answer this question, it will be crucial to analyze a much higher number of isolates.
Biofilm Resistance to Antimicrobial Agents and Mechanisms of Host Defense
Biofilms have a strongly increased capacity to resist antibiotic treatment and attacks by human host defenses (Costerton et al., 1999) . However, the mechanisms underlying this phenomenon are poorly understood. Resistance to antibiotics was reported to involve a series of different mechanisms (Mah and O'Toole, 2001 ). First, the biofilm matrix may represent a diffusion barrier for antibiotics. This may be the case for some but certainly not all antibiotics, and appears to be dependent on their physicochemical characteristics. Second, biofilm cells have a different physiological status compared with actively growing, planktonic cells, which minimizes their sensitivity to antibiotics that target active cell processes. Third, expression of specific protective molecules may be higher in the biofilm mode of growth, and antibiotics may even directly promote the expression of protective mechanisms. All of these mechanisms certainly contribute to biofilm resistance to antibiotics in vitro, but whether any of them matter in vivo remains unknown.
A hallmark of chronic infections is the incapacity of the acquired immune system to clear the infection. In the case of biofilms, this is believed to be mostly due to the shielding of recognizable epitopes by lowly immunogenic matrix components. Whether the mechanisms of innate host defense may efficiently attack bacteria in established biofilms is poorly understood. The most important innate host defense mechanism is the elimination of bacteria by professional phagocytes. Activation of these immune cells depends on the recognition of pathogen-associated molecular patterns, but these may also be hidden by matrix components that do not themselves trigger phagocyte activation efficiently. The notion that phagocytes are prevented from infiltrating into a biofilm is controversial (Leid et al., 2002) . However, it is certainly imaginable that the biofilm matrix provides at least some protection from phagocyte intrusion, as was postulated early (Krieg et al., 1988; Vaudaux et al., 1985) .
Antibiofilm Therapy
Finding a cure for biofilm infection is one of the most difficult and challenging tasks in antibacterial drug development. Clearly, there has not been much success yet. This is because there are significant problems associated with all approaches that have been undertaken or conceived to develop antibiofilm therapeutics.
Theoretically, biofilm formation on indwelling medical devices can be prevented by altering the device's surface to prevent bacterial attachment, or by including antibacterial therapeutics in the device to prevent early stages of biofilm formation. Investigators have achieved some limited success using these approaches (Rodrigues, 2011) , but the fact that biofilms develop on human matrix proteins rather than directly on the device's surface poses a significant problem for this strategy.
Another approach consists of targeting bacterial biofilm determinants. However, it is now clear that different bacteria use chemically different molecules to establish biofilms. Thus, there is a great problem with marketability, even if such an approach could succeed, because only specific bacteria could be targeted. Additionally, one would have to consider that other microbes might take the place of the targeted biofilm formers after they are eliminated.
Are there conserved mechanisms of biofilm formation that may represent the basis for a more broadly applicable biofilm therapeutic? The most frequently proposed such mechanism is QS. However, QS systems are conserved more in Gram-negative than in Gram-positive bacteria. Moreover, the more recent differentiated view of the role of QS in infection argues strongly against this approach (Otto, 2004) . QS inhibitors such as the frequently discussed acyl homoserine lactone (AHL) systemtargeting furanones (Hentzer et al., 2002) or inhibitors of the staphylococcal Agr system (Wright et al., 2005) may have the potential to reduce toxicity in acute infection, but they appear to be counterproductive for chronic biofilm-associated infection. In addition, compounds such as QS inhibitors, which target virulence expression instead of killing the bacteria, were originally believed to have a low potential for triggering the development of resistance. However, resistance to furanone-based QS inhibitors was recently reported (Maeda et al., 2012) , suggesting the need for a thorough reevaluation of this drug development strategy.
Targeting biofilm matrix components directly has also been proposed. For example, the PIA/PNAG exopolysaccharide is being evaluated as a vaccine target (Maira-Litran et al., 2004) . It was reported that the enzyme dispersin B specifically degrades PIA/PNAG (Kaplan et al., 2003) . The use of a degradative enzyme may work well in vitro, but it is hard to imagine that it would work during infection. Finally, the development of antisera against antigens that are expressed strongly in biofilms has been proposed (Harro et al., 2010) . However, the problem is less that humans would not be able to produce opsonic QS systems (such as the staphylococcal Agr shown here) contribute to maturation and dispersal of biofilms. Accordingly, biofilms of an Agr QS wild-type strain, as shown by CLSM in the middle, contain channels between cellular agglomerations. Active expression of the QS system (as shown on the top right in green, using an agr promoter gfp fusion construct) leads to dispersal. During prolonged chronic infection, the QS system in biofilms cells may be irreversibly inactivated by mutation, leading to excessive growth of compact biofilms that likely have lost the capacity to disperse and disseminate. The phenotype of a surfactant mutant in which all psm genes controlled by Agr have been inactivated (bottom right) has the same phenotype as the agr QS mutant (bottom left), underlining the importance of surfactants in QS-mediated control of biofilm maturation and detachment.
antibodies than that the bacteria may be inaccessible for professional phagocytes.
Unfortunately, an efficient antibiofilm therapeutic is currently not in sight. This situation calls for intensified molecular research in the biofilm field, most importantly with a more pronounced focus on in vivo relevance. In addition, prophylactic prevention of biofilm formation in hospital settings, such as by increased hygienic measures, should be emphasized.
Conclusions and Future Outlook
Over the past few decades, many biofilm components and mechanistic details of biofilm formation and regulation have been revealed by in vitro research. However, it has also become clear that different experimental setups often lead to strongly varying results, and overall, it is difficult to draw conclusions from in vitro biofilm research with regard to in vivo biofilm-associated infection. Even important new concepts in the biofilm field, such as the contribution of eDNA to biofilm formation, have not yet been confirmed to have in vivo relevance. To address this issue, we need to have a stronger focus on (1) developing and using appropriate animal models of biofilmassociated infection, and (2) evaluating how clinical samples from biofilm infections can be obtained and analyzed to provide more detailed information on in vivo biofilms. For example, recent advances in genome-wide transcriptomic profiling of such samples will allow us to gain more detailed insight into the physiological processes of in vivo biofilms. Furthermore, especially in the Pseudomonas field, biofilm researchers have frequently used strains that are characteristic of acute infection rather than biofilm. The use of such strains should be discontinued in biofilm research except for the analysis of general molecular mechanisms. Biofilm researchers need to reevaluate in vitro and in vivo experimental approaches thoroughly and determine which of these approaches will provide a valid representation of biofilm-associated infection, especially given the urgent need to develop antibiofilm therapeutics.
